Biocryst Pharmaceuticals Presents BCX4161 Phase 1 Trial And Kallikrein Inhibition Assay Results
Published: Mar 03, 2014
RESEARCH TRIANGLE PARK, N.C., March 1, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikrein inhibitor, BCX4161, together with details of the Company's plasma kallikrein inhibition assay. BCX4161 is currently being evaluated in a Phase 2 clinical trial, OPuS-1, as a potential treatment for the prevention of hereditary angioedema (HAE) attacks.
Help employers find you! Check out all the jobs and post your resume.